The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
By G. Steinbach, P. Lynch, R. Phillips, M. Wallace, E. Hawk, G. Gordon, Naoki Wakabayashi, B. Saunders, Yu Shen, T. Fujimura and 14 more. New England Journal of Medicine, 2000
2,592 citations recorded by the source corpus.
Subfields: Pathology and Forensic Medicine, Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/5780c74e7377ee0cfb7ac539c41405059cde97c4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
In Pharmacology
In Psychiatry and Mental health
Citations in the corpus
- NF-κB: linking inflammation and immunity to cancer development and progression (2005, background): “87 ), and specific COX2 inhibitors, which show little effect on other targets such as IKK-b, were found to be efficacious in reducing tumour load in patients with FA”
- Cytokines in cancer pathogenesis and cancer therapy (2004, background): “The ability of non-steroidal anti-inflammatory agents to reduce tumour formation in several mouse models and in patients at high risk for colon carcinoma supports this ide”
- The Role of COX-2 in Intestinal Inflammation and Colorectal Cancer (2009, positive): “…the evidence that treatment of FAP patients with celecoxib significantly reduced the polyp burden in a randomized controlled trial led to the Food and Drug Administration approval of celecoxib (brand name Celebrex) for use in patients with FAP at 400mg twice a day (Steinbach et al., 2000).”
- Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. (2003, background): “It is possible that a higher dose is necessary to influence neuronal survival; a high dose of celecoxib, above the standard antiinflammatory dose, is required to influence neoplastic transformation in the gastrointestinal tract.(25) It is also possible that a period of exposure to antiinflammatory t”
- Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 (2001, methodology): “In this study, 400 mg of celecoxib given twice daily for 6 months reduced the number, size and overall colorectal polyp burden in FAP patients by 31% compared with placeb”
- The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. (2009, background): “Similarly, in a study of patients with familial adenomatous polyposis (FAP), administration of Celecoxib was associated with regression of adenomas of both the colon and the rectum [31].”
- COX‐2 is expressed in human pulmonary, colonic, and mammary tumors (2000, background): “Because this trial did not have a cancer endpoint, additional clinical data will be necessary to determine whether COX-2 inhibitors provide an anticancer benefit.(22) There is also evidence that some NSAIDs such as sulindac, possess anticancer effects that are independent of COX.”